Nat. Genet. 42, 303–312 (2010); published online 28 February 2010; corrected after print 24 February 2011
In the version of this article initially published, the first and second paragraphs of the Results incorrectly stated that the C14ORF133 gene product was a previously unidentified protein and that no antibody against the C14ORF133 gene product (VIPAR) was available. In fact, an earlier study (ref. 20 in the original manuscript) reported functional analyses of the C14ORF133 gene product (also called SPE-39), described the generation of a polyclonal antibody against human SPE-39 and reported an interaction between SPE-39 and VPS33B, similar to the interaction shown in Figure 1b. These errors have been corrected in the HTML and PDF versions of the article.
The online version of the original article can be found at 10.1038/ng.538
About this article
Cite this article
Cullinane, A., Straatman-Iwanowska, A., Zaucker, A. et al. Correction: Corrigendum: Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet 43, 277 (2011). https://doi.org/10.1038/ng0311-277a